Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Bristol-Myers Squibb | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Bristol-Myers Squibb

Growth driven by Opdivo, Eliquis

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Bristol-Myers Squibb

4Q Revenues: $5.2 billion (+22%)

4Q Earnings: $894 million (loss of $197 million 4Q15)

FY Revenues: $19.4 billion (+17%)

FY Earnings: $4.5 billion (earnings were $1.6 billion FY15)

Comments: Growth was driven by key products, Opdivo, with $3.8 billion in sales, up from $942 million FY15, and Eliquis, with sales of $3.3 billion, up 80%. Sprycel sales were up 13% to $1.8 billion. Yervoy sales were down 6% to $1.1 billion. Virology sales slipped for the company’s four franchises. The hepatitis C franchise sales were down 51% to $226 million due to competing products from Gilead and AbbVie. HIV franchises for Sustiva and Reyataz were down 21% and 24% to $246 million and $206 million, respectively, and hepatitis B drug Baraclude sales were down 4% to $296 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters